QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-outperform-on-cencora-lowers-price-target-to-283

Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and lowers the price target from $287 to $283.

 opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurers

Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claim...

 jp-morgan-maintains-overweight-on-cencora-raises-price-target-to-287

JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $280 to $287.

Core News & Articles

Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Allia...

Core News & Articles

Transaction HighlightsWalgreens Boots Alliance announces sale of all remaining unencumbered shares of Cencora, Inc. for proceed...

 wells-fargo-maintains-equal-weight-on-cencora-raises-price-target-to-249

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Equal-Weight and raises the price target from $236 to...

 baird-maintains-outperform-on-cencora-raises-price-target-to-287

Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $285 to $287.

 abbvie-appeals-to-supreme-court-over-attorney-client-privilege-in-long-standing-androgel-case

AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-clien...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION